The Chemical Heritage Foundation (CHF) will present the 2013 Pittcon Heritage Award in honor of Gunther Laukien (1924?1997), the founder of the Bruker group of companies.
The Chemical Heritage Foundation (CHF) will present the 2013 Pittcon Heritage Award in honor of Günther Laukien (1924–1997), the founder of the Bruker group of companies. Jointly sponsored by the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (Pittcon) and CHF, the award recognizes outstanding individuals whose entrepreneurial careers have shaped the scientific instrumentation community, inspired achievement, promoted public understanding of the modern instrumentation sciences, and highlighted the role of analytical chemistry in world economies. The 12th annual award will be presented at Pittcon 2013, which will be held in Philadelphia for the first time in its 64-year history.
“Dr. Günther Laukien is one of the great pioneers in the field of nuclear magnetic resonance spectroscopy,” said Thomas R. Tritton, president and CEO of CHF. “In the early 1960s he saw a need for high-power solids and high-resolution liquid NMR spectrometers and founded the original Bruker Physik AG to develop, make, and distribute the new devices. Within a decade his innovative NMR and EPR systems were sold around the world, and were later complemented by preclinical MRI, FT-IR, FT-Raman, and mass spectrometers.”
Laukien’s son Frank Laukien, Ph.D., president and CEO of Bruker Corporation today, will receive the Pittcon Heritage Award in his father’s honor at Pittcon.
An Interview with AES Mid-Career Award Recipient Jason Dwyer
July 25th 2024Jason Dwyer of the University of Rhode Island has been named the recipient of the American Electrophoresis Society’s Mid-Career Award, which honors exceptional contributions to the field of electrophoresis, microfluidics, and related areas by an individual who is currently in the middle of their career.
Glucose's Impact on Brain Cancer Cells Unveiled Through Raman Imaging
July 25th 2024Researchers have used Raman spectroscopy and chemometric methods to reveal how glucose affects normal and cancerous brain cell metabolism. Their findings highlight specific biomarkers that can distinguish metabolic changes, potentially aiding in cancer research and treatment.